A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy.
The parametric response map (PRM) was evaluated as an early surrogate biomarker for monitoring treatment-induced tissue alterations in patients with head and neck squamous cell carcinoma (HNSCC). Diffusion-weighted magnetic resonance imaging (DW-MRI) was performed on 15 patients with HNSCC at baseline and 3 weeks after treatment initiation of a nonsurgical organ preservation therapy (NSOPT) using concurrent radiation and chemotherapy. PRM was applied on serial apparent diffusion coefficient (ADC) maps that were spatially aligned using a deformable image registration algorithm to measure the tumor volume exhibiting significant changes in ADC (PRM(ADC)). Pretherapy and midtherapy ADC maps, quantified from the DWIs, were analyzed by monitoring the percent change in whole-tumor mean ADC and the PRM metric. The prognostic values of percentage change in tumor volume and mean ADC and PRM(ADC) as a treatment response biomarker were assessed by correlating with tumor control at 6 months. Pixel-wise differences as part of PRM(ADC) analysis revealed regions where water mobility increased. Analysis of the tumor ADC histograms also showed increases in mean ADC as early as 3 weeks into therapy in patients with a favorable outcome. Nevertheless, the percentage change in mean ADC was found to not correlate with tumor control at 6 months. In contrast, significant differences in PRM(ADC) and percentage change in tumor volume were observed between patients with pathologically different outcomes. Observations from this study have found that diffusion MRI, when assessed by PRM(ADC), has the potential to provide both prognostic and spatial information during NSOPT of head and neck cancer.
Galbán
Craig J
CJ
The University of Michigan Medical School, Ann Arbor, MI, USA.
Mukherji
Suresh K
SK
Chenevert
Thomas L
TL
Meyer
Charles R
CR
Hamstra
Daniel A
DA
Bland
Peyton H
PH
Johnson
Timothy D
TD
Moffat
Bradford A
BA
Rehemtulla
Alnawaz
A
Eisbruch
Avraham
A
Ross
Brian D
BD
J Clin Oncol. 2008 Jul 10;26(20):3387-94
18541899
Transl Oncol. 2008 Dec;1(4):187-94
19043529
Clin Cancer Res. 2009 Feb 1;15(3):986-94
19188170
Acta Radiol. 2008 Nov;49(9):1079-84
18785024
Neoplasia. 2007 Dec;9(12):1160-5
18084623
Neoplasia. 2009 Mar;11(3):237-46, 1p following 246
19242605
Neoplasia. 2009 Mar;11(3):247-59, 2p following 259
19242606
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Neoplasia. 2009 Jun;11(6):574-82, 1 p following 582
19484146
Mol Ther. 2004 Nov;10(5):916-28
15509509
Nat Med. 2009 May;15(5):572-6
19377487
Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):958-65
12829130
Med Image Anal. 1997 Apr;1(3):195-206
9873906
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64
16267128
Neoplasia. 2009 Feb;11(2):102-25
19186405
NMR Biomed. 1995 Nov-Dec;8(7-8):289-96
8739267
J Clin Oncol. 2007 Sep 10;25(26):4104-9
17827460
AJNR Am J Neuroradiol. 2008 Jan;29(1):40-4
17921228
Neoplasia. 2007 May;9(5):392-400
17534444
Magn Reson Med. 1999 Nov;42(5):952-62
10542355
Neoplasia. 2007 Dec;9(12):1003-11
18084607
J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36
11121466
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):960-71
17141979
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5524-9
15805192
Neoplasia. 2006 Apr;8(4):259-67
16756718
Strahlenther Onkol. 2003 Sep;179(9):641-9
14628131
Clin Cancer Res. 1997 Sep;3(9):1457-66
9815831
Radiology. 2001 Sep;220(3):621-30
11526259
Curr Opin Oncol. 2006 May;18(3):234-9
16552234
Neoplasia. 2004 Nov-Dec;6(6):831-7
15720810
J Clin Oncol. 2003 Mar 15;21(6):1094-100
12637476